Guardion Health Sciences Future Growth

Future criteria checks 1/6

Guardion Health Sciences is forecast to grow earnings and revenue by 35.8% and 12.5% per annum respectively while EPS is expected to grow by 47.6% per annum.

Key information

35.8%

Earnings growth rate

47.6%

EPS growth rate

Personal Products earnings growth	8.4%
Revenue growth rate	12.5%
Future return on equity	n/a
Analyst coverage	Low
Last updated	22 Feb 2023

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:0QTA - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2024	14	-7	N/A	N/A	1
12/31/2023	12	-8	N/A	N/A	1
12/31/2022	11	-8	N/A	N/A	1
9/30/2022	11	-21	-8	-8	N/A
6/30/2022	11	-22	-8	-8	N/A
3/31/2022	9	-25	-11	-10	N/A
12/31/2021	7	-25	-11	-11	N/A
9/30/2021	5	-14	-11	-11	N/A
6/30/2021	2	-13	-11	-11	N/A
3/31/2021	2	-9	-9	-9	N/A
12/31/2020	2	-9	-8	-8	N/A
9/30/2020	2	-9	-8	-8	N/A
6/30/2020	2	-9	-8	-8	N/A
3/31/2020	1	-12	-7	-7	N/A
12/31/2019	1	-11	-6	-6	N/A
9/30/2019	1	-8	-5	-5	N/A
6/30/2019	1	-8	-4	-4	N/A
3/31/2019	1	-7	-4	-3	N/A
12/31/2018	1	-8	-4	-4	N/A
9/30/2018	1	-9	-5	-5	N/A
6/30/2018	1	-9	-5	-5	N/A
3/31/2018	1	-8	-4	-4	N/A
12/31/2017	0	-6	-3	-3	N/A
9/30/2017	0	-6	-2	-2	N/A
6/30/2017	0	-6	-2	-2	N/A
3/31/2017	0	-6	-2	-2	N/A
12/31/2016	0	-7	-2	-2	N/A
9/30/2016	0	-5	-2	-2	N/A
6/30/2016	0	-6	N/A	-1	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 0QTA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 0QTA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 0QTA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 0QTA's revenue (12.5% per year) is forecast to grow faster than the German market (4.6% per year).

High Growth Revenue: 0QTA's revenue (12.5% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 0QTA's Return on Equity is forecast to be high in 3 years time

Guardion Health Sciences Future Growth

Future criteria checks 1/6

Key information

Recent future growth updates

Recent updates

Guardion Health Sciences Expects the Official Delisting of its Common Stock to be Effective October 21, 2024

Guardion Health Sciences, Inc. Appoints Mark Goldstone as Interim Chief Executive Officer, Effective as of October 18, 2024

Guardion Health Sciences, Inc. Declares Dividend, Payable on September 23, 2024

Doctor's Best, Inc. agreed to acquire Activ Nutritional, LLC. from Guardion Health Sciences, Inc. (NasdaqCM:GHSI) for $17.2 million.

Guardion Health Sciences, Inc., Annual General Meeting, Nov 21, 2023

Guardion Health Sciences, Inc. Announces Executive Changes

Guardion Health Sciences, Inc. Announces Executive Changes

Guardion Health Sciences Regains Compliance with Nasdaq Continued Listing Requirements

Guardion Health Sciences, Inc. Announces Clinical Results Indicating that Viactiv® Omega Boost™ Gel Bites Increase Omega-3 Levels in Just 4 weeks

Guardion Health Sciences, Inc., Annual General Meeting, Jun 16, 2022

Guardion Health Sciences, Inc. Announces New Viactiv® Omega Boost Gel Bites Now Available for Purchase Via Viactiv® Shopify Store

Guardion Health Sciences, Inc. Launches New Viactiv® Omega BOOST™ Passion Fruit Flavored Gel Bites

Guardion Health Sciences to Wind Down VectorVision Business Operations and Focus on Exploiting VectorVision Intellectual Property

Guardion Health Sciences, Inc. (NasdaqCM:GHSI) completed the acquisition of Activ Nutritional, LLC from Adare Pharmaceuticals, Inc.

Guardion Health Sciences, Inc. (NasdaqCM:GHSI) entered into an Equity Purchase Agreement to acquire Activ Nutritional, LLC from Adare Pharmaceuticals, Inc. for $26 million.

Guardion Health Sciences, Inc. Initiates Placebo-Controlled Clinical Trial Involving Proprietary GlaucoCetin® Product

Guardion Health Sciences Regains Compliance with Nasdaq Minimum Bid Price Rule

Guardion Health Sciences Announces 1-For-6 Reverse Stock Split to Comply with the $1.00 Per Share Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

New 90-day high: €1.06

Guardion Health Sciences Receives Regulatory Product Registration Approval for Second Immune Support Dietary Supplement Designed and Produced by Guardion Health Sciences

Nasdaq Grants Guardion Health Sciences an Extension to March 15, 2021 to Regain Compliance with the $1.00 Minimum Bid Price Rule

New 90-day high: €0.77

HO WAH GENTING BERHAD Appoints Guardion Health Sciences, Inc to Design and Manufacture an Exclusive Custom Immune Support Nutraceutical Formula

Guardion Health Sciences, Inc. Appoints Bret Scholtes as Chief Executive Officer Commencing January 6, 2021

New 90-day high: €0.26

Guardion Health Sciences Announces Development of New Vision/Energy Support Drink – EPIQ-V

New 90-day high: €0.23

Third quarter 2020 earnings released: US$0.024 loss per share

Guardion Health Sciences Announces Investigator-Initiated Clinical Trial of Lumega-Z

New 90-day low - €0.23

First half earnings released

Guardion Health Sciences, Inc. to Report Q2, 2020 Results on Aug 12, 2020

New 90-day low - €0.34

New 90-day low - €0.35

Guardion Health Sciences, Inc.(NasdaqCM:GHSI) dropped from Russell Microcap Index

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies